GAIA and Daiichi Sankyo Partner to Commercialise Digital Therapeutic for Cardiovascular Care
Friday, March 06, 2026
GAIA and Daiichi Sankyo Europe have entered into an exclusive strategic partnership to commercialise the digital therapeutic lipodia, subject to regulatory approval.
Cardiovascular diseases remain the leading cause of death in Europe, accounting for more than 10,000 deaths each day. However, a large proportion of heart disease and stroke cases are considered preventable. Major risk factors include high blood pressure, high cholesterol, diabetes, smoking, obesity and lack of physical activity, while poor diet, excessive alcohol intake and stress also contribute.
Lipodia is based on evidence-based behavioural health science and incorporates psychological and psychotherapeutic approaches. The digital therapeutic adapts to individual patient needs through interactive dialogue and provides additional features designed to help users adopt healthier daily routines. It is a fully automated therapy that can be accessed on most connected devices, allowing flexible and location-independent use.
The therapy is designed to support adults living with hypercholesterolaemia. The collaboration combines GAIA’s experience in developing clinically validated digital and non-pharmacological therapies with Daiichi Sankyo Europe’s expertise in cardiovascular risk management. Through this partnership, the companies aim to address gaps in long-term cardiovascular care by using digital technology to encourage sustainable lifestyle and behavioural changes among patients.
Under the agreement, Daiichi Sankyo Europe has secured exclusive rights to lipodia. The partnership initially focuses on Germany, the largest healthcare market in Europe, with the possibility of expansion to other major European markets. The collaboration reflects the growing need for integrated healthcare approaches that combine medicines with digital tools to support behavioural change and long-term disease management.
To ensure broad patient access, GAIA plans to apply for reimbursement once data from the pivotal Phase III randomised controlled trial become available. If approved, the therapy could be reimbursed through Germany’s Digital Health Applications (DiGA) pathway and prescribed by physicians as part of routine cardiovascular care.
The partnership aims to position lipodia as a scalable digital solution that complements existing treatment options and supports improved management of cardiovascular disease across Europe.
Source: businesswire.com
